person · Reporting owner
Heffernan Michael Thomas
Disclosed activity across 9 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | Director | June 02, 2021 | June 03, 2021 |
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Director | June 02, 2026 | June 04, 2026 |
| Biohaven Ltd.BHVN · Entity 4379 | Director | April 28, 2026 | May 01, 2026 |
| Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269 | Director | October 03, 2022 | October 03, 2022 |
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director | February 10, 2025 | February 12, 2025 |
| SYNLOGIC, INC.SYBX · Entity 7801 | Director | June 22, 2023 | June 26, 2023 |
| Trevi Therapeutics, Inc.TRVI · Entity 4387 | Director | September 15, 2026 | September 17, 2026 |
| enGene Therapeutics Inc.ENGN · Entity 6638 | Director | June 16, 2026 | June 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date June 02, 2021 · Filed June 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,586 |
Reported balance
After 2021-06-02 transaction · row 1
1 source rowRow 1 · 2021-06-02 · Grant · Acquired 13,700 · Balance 48,586 F1: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"), as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2031-06-02 | Direct | 20,100 |
Reported balance
After 2021-06-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-02 · Grant · Acquired 20,100 · Balance 20,100 F2: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2014 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"), as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.
F2: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2014 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.
Avalo Therapeutics, Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.96 · Expires 2036-06-02 | Direct | 29,500 |
Reported balance
After 2026-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 29,500 · Balance 29,500 F1: The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date.
Biohaven Ltd.
Report date April 28, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2036-04-28 | Direct | 68,693 |
Reported balance
After 2026-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-28 · Grant · Acquired 68,693 · Balance 68,693 F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Biohaven Pharmaceutical Holding Co Ltd.
Report date October 03, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 3,320 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.33 · Expires 2032-04-28 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-03 · Disposition to issuer · Disposed 8,239 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.17 · Expires 2031-05-05 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-03 · Disposition to issuer · Disposed 11,996 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.30 · Expires 2030-01-31 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-03 · Disposition to issuer · Disposed 26,200 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").
F2: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.
F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
COLLEGIUM PHARMACEUTICAL, INC
Report date February 10, 2025 · Filed February 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,328 |
Reported balance
After 2025-02-10 transaction · row 1
1 source rowRow 1 · 2025-02-10 · Grant · Acquired 4,820 · Balance 50,328 F1: Reflects the grant of fully-vested restricted stock units ("RSUs") granted as compensation for the Reporting Person's service as interim Chief Executive Officer in 2024. Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of fully-vested restricted stock units ("RSUs") granted as compensation for the Reporting Person's service as interim Chief Executive Officer in 2024. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
SYNLOGIC, INC.
Report date June 22, 2023 · Filed June 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2033-06-22 | Direct | 30,000 |
Reported balance
After 2023-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-22 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.
Trevi Therapeutics, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,351 |
Ending reported balance
After 2026-09-15 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 18,421 · Balance 24,772 Row 2 · 2026-09-15 · Sale · Disposed 18,321 · Balance 6,451 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.80 to $15.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. Row 3 · 2026-09-15 · Sale · Disposed 100 · Balance 6,351 F1: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. Row 4 · 2026-09-15 · Exercise / conversion · Acquired 21,052 · Balance 27,403 Row 5 · 2026-09-15 · Sale · Disposed 20,952 · Balance 6,451 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.80 to $15.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. Row 6 · 2026-09-15 · Sale · Disposed 100 · Balance 6,351 F1: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.04 | Direct | 0 |
Reported balance
After 2026-09-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-15 · Exercise / conversion · Disposed 18,421 · Balance 0 F3: These options were granted on February 28, 2017. The 18,421 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments. F4: These options, which were awarded on February 28, 2017, would otherwise expire and become forfeitable on February 27, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.33 | Direct | 0 |
Reported balance
After 2026-09-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-15 · Exercise / conversion · Disposed 21,052 · Balance 0 F5: These options were granted on December 20, 2017. The 21,052 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments. F6: These options, which were awarded on December 20, 2017, would otherwise expire and become forfeitable on December 19, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.80 to $15.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3: These options were granted on February 28, 2017. The 18,421 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments.
F4: These options, which were awarded on February 28, 2017, would otherwise expire and become forfeitable on February 27, 2027.
F5: These options were granted on December 20, 2017. The 21,052 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments.
F6: These options, which were awarded on December 20, 2017, would otherwise expire and become forfeitable on December 19, 2027.
enGene Therapeutics Inc.
Report date June 16, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2036-06-16 | Direct | 31,000 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 31,000 · Balance 31,000 F1: This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
KERYX BIOPHARMACEUTICALS INC
Report date December 12, 2018 · Filed December 13, 2018
Section 16 reporting ended · disclosed 2018-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-12 transaction · row 1
1 source rowRow 1 · 2018-12-12 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement. F2: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 16,666 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. |
| Stock OptionSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-12-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-12-12 · Disposition to issuer · Disposed 110,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement.
F2: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 16,666 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018.
F3: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 17, 2026 20:55 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionStock Option (right to buy) · Derivative | 21,052 | $0.00 Strike: $3.33 | $0.00 |
DisclosureSEC source: 0001193125-26-394456 · ownership.xml · derivative · entry 8 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,052 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These options were granted on December 20, 2017. The 21,052 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments. F6 · derivative.expiration_date: These options, which were awarded on December 20, 2017, would otherwise expire and become forfeitable on December 19, 2027. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:55 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionStock Option (right to buy) · Derivative | 18,421 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001193125-26-394456 · ownership.xml · derivative · entry 7 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,421 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options were granted on February 28, 2017. The 18,421 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments. F4 · derivative.expiration_date: These options, which were awarded on February 28, 2017, would otherwise expire and become forfeitable on February 27, 2027. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:55 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | SaleCommon Stock | 100 | $15.88 | $1,588.00 |
DisclosureSEC source: 0001193125-26-394456 · ownership.xml · nonDerivative · entry 6 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,351 F1 · acquired: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:55 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | SaleCommon Stock | 20,952 | $15.09 | $316,165.68 |
DisclosureSEC source: 0001193125-26-394456 · ownership.xml · nonDerivative · entry 5 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,451 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.80 to $15.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · acquired: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:55 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionCommon Stock | 21,052 | $3.33 | $70,103.16 |
DisclosureSEC source: 0001193125-26-394456 · ownership.xml · nonDerivative · entry 4 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:55 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | SaleCommon Stock | 100 | $15.88 | $1,588.00 |
DisclosureSEC source: 0001193125-26-394456 · ownership.xml · nonDerivative · entry 3 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,351 F1 · acquired: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:55 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | SaleCommon Stock | 18,321 | $15.09 | $276,463.89 |
DisclosureSEC source: 0001193125-26-394456 · ownership.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,451 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.80 to $15.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · acquired: This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:55 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | Exercise / conversionCommon Stock | 18,421 | $3.04 | $55,999.84 |
DisclosureSEC source: 0001193125-26-394456 · ownership.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,772 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 21:38 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 31,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0000929638-26-002258 · form4.xml · derivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Shares · 31,000 shares Expires 2036-06-16 F1 · derivative.exercise_date: This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 20:05 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantNonstatutory Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $13.45 | $0.00 |
DisclosureSEC source: 0001193125-26-257366 · ownership.xml · derivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-06-02 F1 · derivative.exercise_date: This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 29,500 | $0.00 Strike: $13.96 | $0.00 |
DisclosureSEC source: 0001448914-26-000004 · form4-06042026_040603.xml · derivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,500 Underlying: Common Stock · 29,500 shares Expires 2036-06-02 F1 · derivative.exercise_date: The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date. Read SEC document |
| April 28, 2026 Filed May 1, 2026 00:08 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 68,693 | $0.00 Strike: $9.61 | $0.00 |
DisclosureSEC source: 0001448914-26-000002 · wk-form4_1777594127.xml · derivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,693 Underlying: Common Shares · 68,693 shares Expires 2036-04-28 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 20:06 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0000929638-25-002557 · form4.xml · derivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Shares · 45,000 shares Expires 2035-07-08 F1 · derivative.exercise_date: This option vests at 1/3 on each of the first, second and third anniversaries of Mr. Heffernan's date of appointment to the Board, which was July 8, 2025. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:19 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 29,500 | $0.00 Strike: $4.47 | $0.00 |
DisclosureSEC source: 0001578563-25-000320 · primary_doc.xml · derivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,500 Underlying: Common Stock · 29,500 shares Expires 2035-06-17 F1 · derivative.exercise_date: The stock option vests 100% on the first anniversary of the date of grant, subject to the Eligible Director's continued service on such vesting date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantNonstatutory Stock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0000950170-25-086111 · ownership.xml · derivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: This option was granted on June 11, 2025. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. Read SEC document |
| May 05, 2025 Filed May 7, 2025 21:15 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 31,716 | $0.00 Strike: $22.62 | $0.00 |
DisclosureSEC source: 0001935979-25-000046 · wk-form4_1746652496.xml · derivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,716 Underlying: Common Shares · 31,716 shares Expires 2035-05-05 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 5, 2026 or (b) the date of the 2026 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| March 25, 2025 Filed Mar 26, 2025 20:07 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $8.54 | $0.00 |
DisclosureSEC source: 0001578563-25-000193 · primary_doc.xml · derivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-03-25 F1 · derivative.exercise_date: The stock option vests in three substantially equal annual installments on the first, second and third anniversary of the date of grant, subject to the Eligible Director's continued service on each such vesting date. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:10 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 4,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-002181 · form4.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,328 F1 · shares: Reflects the grant of fully-vested restricted stock units ("RSUs") granted as compensation for the Reporting Person's service as interim Chief Executive Officer in 2024. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 20:30 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantNonstatutory Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0000950170-24-073727 · ownership.xml · derivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: This option was granted on June 13, 2024. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. Read SEC document |
| May 16, 2024 Filed May 16, 2024 23:21 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 7,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-010537 · form4.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,508 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. Read SEC document |
| April 30, 2024 Filed May 2, 2024 23:33 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Option (Right to Buy) · Derivative | 16,592 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001562180-24-003754 · primarydocument.xml · derivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,592 Underlying: Common Shares · 16,592 shares Expires 2034-04-30 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2025 or (b) the date of the 2025 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:00 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantNonstatutory Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001209191-23-040288 · doc4.xml · derivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-27 F1 · derivative.exercise_date: This option was granted on June 28, 2023. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 18:20 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000950170-23-029802 · ownership.xml · derivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-22 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:40 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 9,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-011818 · form4.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,815 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 18, 2024, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| May 02, 2023 Filed May 4, 2023 21:51 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Option (Right to Buy) · Derivative | 52,906 | $0.00 Strike: $13.20 | $0.00 |
DisclosureSEC source: 0001562180-23-003941 · primarydocument.xml · derivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,906 Underlying: Common Shares · 52,906 shares Expires 2033-05-02 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 2, 2024 or (b) the date of the 2024 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| December 27, 2022 Filed Dec 28, 2022 00:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 3,820 | $0.00 Strike: $16.15 | $0.00 |
DisclosureSEC source: 0001062993-22-024501 · form4.xml · derivative · entry 12 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,820 shares Expires 2026-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, initially representing a right to purchase a total of 109,005 shares, is fully vested and exercisable. Read SEC document |
| December 27, 2022 Filed Dec 28, 2022 00:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 15,995 | $0.00 Strike: $16.15 | $0.00 |
DisclosureSEC source: 0001062993-22-024501 · form4.xml · derivative · entry 11 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,820 Underlying: Common Stock · 15,995 shares Expires 2026-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, initially representing a right to purchase a total of 109,005 shares, is fully vested and exercisable. Read SEC document |
| December 27, 2022 Filed Dec 28, 2022 00:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 3,820 | $24.16 | $92,291.20 |
DisclosureSEC source: 0001062993-22-024501 · form4.xml · nonDerivative · entry 8 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,023 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2022. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4). Read SEC document |
| December 27, 2022 Filed Dec 28, 2022 00:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 3,820 | $16.15 | $61,693.00 |
DisclosureSEC source: 0001062993-22-024501 · form4.xml · nonDerivative · entry 7 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,843 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2022 Filed Dec 28, 2022 00:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 15,995 | $23.63 | $377,961.85 |
DisclosureSEC source: 0001062993-22-024501 · form4.xml · nonDerivative · entry 6 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,023 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2022. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3). Read SEC document |
| December 27, 2022 Filed Dec 28, 2022 00:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 15,995 | $16.15 | $258,319.25 |
DisclosureSEC source: 0001062993-22-024501 · form4.xml · nonDerivative · entry 5 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 00:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 4,989 | $0.00 Strike: $16.15 | $0.00 |
DisclosureSEC source: 0001062993-22-024501 · form4.xml · derivative · entry 10 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,815 Underlying: Common Stock · 4,989 shares Expires 2026-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, initially representing a right to purchase a total of 109,005 shares, is fully vested and exercisable. Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 00:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 4,989 | $23.00 | $114,747.00 |
DisclosureSEC source: 0001062993-22-024501 · form4.xml · nonDerivative · entry 4 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,023 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2). Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 00:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 4,989 | $16.15 | $80,572.35 |
DisclosureSEC source: 0001062993-22-024501 · form4.xml · nonDerivative · entry 3 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2022 Filed Dec 28, 2022 00:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 237 | $0.00 Strike: $16.15 | $0.00 |
DisclosureSEC source: 0001062993-22-024501 · form4.xml · derivative · entry 9 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,804 Underlying: Common Stock · 237 shares Expires 2026-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, initially representing a right to purchase a total of 109,005 shares, is fully vested and exercisable. Read SEC document |
| December 22, 2022 Filed Dec 28, 2022 00:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 237 | $23.00 | $5,451.00 |
DisclosureSEC source: 0001062993-22-024501 · form4.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,023 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2022. Read SEC document |
| December 22, 2022 Filed Dec 28, 2022 00:17 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 237 | $16.15 | $3,827.55 |
DisclosureSEC source: 0001062993-22-024501 · form4.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 00:28 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 46,600 | $0.00 Strike: $16.15 | $0.00 |
DisclosureSEC source: 0001062993-22-024356 · form4.xml · derivative · entry 9 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,041 Underlying: Common Stock · 46,600 shares Expires 2026-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, initially representing a right to purchase a total of 109,005 shares, is fully vested and exercisable. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 00:28 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 46,600 | $23.11 | $1,076,926.00 |
DisclosureSEC source: 0001062993-22-024356 · form4.xml · nonDerivative · entry 6 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,023 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2022. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4). Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 00:28 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 46,600 | $16.15 | $752,590.00 |
DisclosureSEC source: 0001062993-22-024356 · form4.xml · nonDerivative · entry 5 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 00:28 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 33,758 | $0.00 Strike: $16.15 | $0.00 |
DisclosureSEC source: 0001062993-22-024356 · form4.xml · derivative · entry 8 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,641 Underlying: Common Stock · 33,758 shares Expires 2026-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, initially representing a right to purchase a total of 109,005 shares, is fully vested and exercisable. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 00:28 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 33,758 | $23.08 | $779,134.64 |
DisclosureSEC source: 0001062993-22-024356 · form4.xml · nonDerivative · entry 4 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,023 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2022. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3). Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 00:28 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 33,758 | $16.15 | $545,191.70 |
DisclosureSEC source: 0001062993-22-024356 · form4.xml · nonDerivative · entry 3 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2022 Filed Dec 22, 2022 00:28 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 3,606 | $0.00 Strike: $16.15 | $0.00 |
DisclosureSEC source: 0001062993-22-024356 · form4.xml · derivative · entry 7 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,399 Underlying: Common Stock · 3,606 shares Expires 2026-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, initially representing a right to purchase a total of 109,005 shares, is fully vested and exercisable. Read SEC document |
| December 19, 2022 Filed Dec 22, 2022 00:28 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 3,606 | $23.04 | $83,082.24 |
DisclosureSEC source: 0001062993-22-024356 · form4.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,023 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2). Read SEC document |
| December 19, 2022 Filed Dec 22, 2022 00:28 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 3,606 | $16.15 | $58,236.90 |
DisclosureSEC source: 0001062993-22-024356 · form4.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 23:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 7,904 | $0.00 Strike: $14.57 | $0.00 |
DisclosureSEC source: 0001062993-22-023905 · form4.xml · derivative · entry 14 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,904 shares Expires 2029-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: All of the 7,904 option shares are exercisable. Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 23:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 94,259 | $0.00 Strike: $15.27 | $0.00 |
DisclosureSEC source: 0001062993-22-023905 · form4.xml · derivative · entry 13 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 94,259 shares Expires 2027-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: All of the 94,259 option shares are exercisable. Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 23:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 59,524 | $0.00 Strike: $14.90 | $0.00 |
DisclosureSEC source: 0001062993-22-023905 · form4.xml · derivative · entry 12 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,524 shares Expires 2025-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: All of the 59,524 option shares are exercisable. Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 23:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 161,687 | $22.16 | $3,582,983.92 |
DisclosureSEC source: 0001062993-22-023905 · form4.xml · nonDerivative · entry 8 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,023 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2022. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.00 to $22.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.